Ace Therapeutics is dedicated to providing pharmaceutical organizations with important cell models for curing schizophrenia as well as comprehensive gene expression analysis and neurotoxicity testing based on these cells to accelerate your drug development process.

Introduction of Cellular Model Development for Schizophrenia

Schizophrenia (SZ) is a complex, highly genetic psychiatric disorder. It affects 1-2% of the world's population and carries significant health and social care costs. Appropriate in vitro and in vivo models are needed to elucidate the pathophysiological mechanisms of SZ and to develop new therapies. cellular models of SZ allow us to reproduce the alterations in brain development and function that underlie the genetic and biochemical aspects of the disease.

Fig. 1 Rational design of SZ models. (Abashkin DA, et al., 2021)

Cellular Model Development Services for Schizophrenia

Ace Therapeutics uses induced pluripotent stem cell (iPSC) technology to build cellular models that can be used to model early neurodevelopmental alterations caused by risk genes or environmental stressors. Our cell models allow the identification and further study of risk factors and the biological pathways they involve. Our cell models can faithfully mimic neurodevelopment and neuronal function becomes possible, in addition, our use of CRISPR editing tools helps to design isogenic cell lines to precisely explore genetic variants in polygenic diseases such as schizophrenia.

We also offer cell model-based research services for schizophrenia that can enhance your understanding of the neurobiological features of the disease. Studies using iPSC-based models of schizophrenia can already be used to study alterations in neural progenitor cell proliferation, alterations in excitatory and inhibitory neurotransmission, and disruptions in synaptic maturation. iPSC-based models can also be used to reveal the impact of genetic risk factors and prenatal environmental damage on the development of schizophrenia and other psychiatric disorders.

We offer cellular models of the following psychiatric disorders, including but not limited to

• Neuroblastoma Model Development for Schizophrenia

We are committed to providing SH-SY5Y neuroblastoma cell models for schizophrenia research and services for anti-schizophrenia drug development based on these cells. Our cellular models are used to study the relationship between schizophrenia-related phenotypic features and pathomorphology, electrophysiology and behavior.

• iPSC-Derived Neural Cell Model Development for Schizophrenia

Our preclinical services include patient iPSC reprogramming, cell line engineering, iPSC-neuronal differentiation, and ASO/siRNA screening. Our researchers and scientists combine in-depth knowledge of cell engineering and RNA therapies to help accelerate your drug development against psychiatric disorders, including individualized drugs.

• Glial Cell Model Development for Schizophrenia

We are committed to providing you with glial cell models for psychiatric research, including oligodendrocytes, astrocytes, and microglia. We can also provide comprehensive gene expression analysis and neurotoxicity testing based on these cells to accelerate your drug development process.

Our Advantages

• Personalized service: Off-the-shelf genealogies available at scale, as well as flexible and efficient customs solutions.
• Consulting science: Industry-leading scientific experts will help develop cost-effective programs to meet your research needs.
• Rigorous quality control protocols: Protocols include, but are not limited to, assessment of cell counts, viability, genomic stability, and expression of profiling markers at the transcriptome and protein levels.

Ace Therapeutics is committed to providing attractive resources for in vitro modeling of psychiatric disorders, toxicity screening, and drug screening. If you are interested in our services, please make an inquiry.

Reference

1. Abashkin DA, et al. Cellular Models in Schizophrenia Research. Int J Mol Sci. 2021, 22(16):8518.